Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

ASC30 oral tablet demonstrated superior PK properties (including a longer t1/2 and higher AUC) to other small molecule oral GLP-1 receptor (GLP-1R) agonists in development, suggesting ASC30 oral ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs ... number of thyroid cancer cases was small, medullary thyroid cancer risk ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... and improvement in some cholesterol parameters, with a very small increase in heart rate.

It has similar efficacy to other GLP1 agonists ... for CV events probably combine to make GLP-1 RAs protective against CV events. However, recent small studies on both animals and humans have ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.